Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Enhertu Gets 2nd Line Breast Cancer Nod in Europe: Daiichi Sankyo
July 20, 2022
- Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
- Konica Minolta’s Cancer Genomic Profiling System Approved in Japan
July 19, 2022
- Kyowa Kirin to Cease Development of Parkinson’s Hopeful KW-6356
July 19, 2022
- Japan Becoming Less Priority Market as Policy Changes Mar Predictability: MSD Exec
July 19, 2022
- Edirol Hits Chinese Market: Chugai
July 19, 2022
- Shionogi COVID Pill Shows Antiviral Activity Against BA.5
July 15, 2022
- Ultragenyx Takes Over Mepsevii Marketing Authorization in Japan
July 15, 2022
- Shingrix Shows Cost-Effectiveness in Japanese Older Adults: GSK Analysis
July 15, 2022
- Pfizer Japan Files COVID-19 Vaccine for Ages 6 Months to 4 Years
July 15, 2022
- Mochida to Discontinue Filgrastim Biosimilars Despite 50% Share
July 14, 2022
- Financially Weak Companies Will Go Under If Annual Price Cuts Continue: Sawai Chair
July 14, 2022
- BMS Japan on Track to Achieve Goals in Mid-Term Biz Plan: Chief
July 14, 2022
- Shionogi’s Four-Day Workweek Not So Popular Yet, but Side Job Plan Gaining Traction
July 13, 2022
- Healios to Provide iPSC Line to RxCell; License Talks with StemAxon Gets Underway
July 13, 2022
- Ex-Novartis Exec Jugo Tsumura Takes Reins at Ferring Japan
July 12, 2022
- Takeda Showcases Manufacturing Line for Cell Therapy Alofisel
July 11, 2022
- Organon Curbs Shipment of Fertility Med Ganirest in Japan
July 11, 2022
- As LOEs Loom, Can Mochida Roll Out Authorized Generics for Lexapro and Lialda?
July 8, 2022
- Shipment Restrictions Continue for Vyndaqel, Vynmac: Pfizer Japan
July 8, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…